Campbell & Co Investment Adviser’s Emergent Biosolutions EBS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$161K	Sell	19,386 -81,118	-81%	-$840K	0.01%	978
2025 Q4	$1.24M	Buy	100,504 +55,896	+125%	+$599K	0.06%	479
2025 Q3	$393K	Buy	+44,608	New	+$347K	0.03%	816
2025 Q2	–	Sell	-21,240	Closed	-$103K	–	1206
2025 Q1	$103K	Buy	+21,240	New	+$176K	0.01%	984
2024 Q4	–	Sell	-47,717	Closed	-$398K	–	1124
2024 Q3	$398K	Buy	+47,717	New	+$434K	0.03%	802
2023 Q3	–	Sell	-16,272	Closed	-$120K	–	1004
2023 Q2	$120K	Buy	+16,272	New	+$151K	0.02%	837
2022 Q1	–	Sell	-5,050	Closed	-$220K	–	744
2021 Q4	$220K	Sell	5,050 -2,900	-36%	-$131K	0.08%	502
2021 Q3	$398K	Buy	+7,950	New	+$481K	0.13%	286
2019 Q4	–	Sell	-8,311	Closed	-$434K	–	689
2019 Q3	$434K	Buy	+8,311	New	+$387K	0.16%	228
2017 Q1	–	Sell	-6,434	Closed	-$211K	–	167
2016 Q4	$211K	Buy	+6,434	New	+$193K	0.65%	85

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Campbell & Co Investment Adviser's EBS Position: Q1 2026 in Review

Campbell & Co Investment Adviser reduced its Emergent Biosolutions (EBS) stake by 81% in Q1 2026, selling an estimated $840K and leaving 19,386 shares worth $161K. The position accounts for 0.01% of the portfolio, ranked #978.

Campbell & Co Investment Adviser first reported a position in EBS in Q4 2016 and has held it in 10 quarters since. The position peaked at $1.24M in Q4 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

Campbell & Co Investment Adviser held 19,386 shares of Emergent Biosolutions worth $161K as of Q1 2026.
Campbell & Co Investment Adviser sold 81,118 Emergent Biosolutions shares in Q1 2026, an estimated $840K.
Emergent Biosolutions made up 0.01% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #978 holding.
Campbell & Co Investment Adviser first reported a position in Emergent Biosolutions in Q4 2016 and has held it in 10 quarters since.
Campbell & Co Investment Adviser's Emergent Biosolutions position peaked at $1.24M in Q4 2025.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.